How to work with us


HADASIT - the innovation company of Hadassah Medical Center,

is the gateway for industry collaborations with Israel’s premier university hospital.

Hadassah is internationally recognized for clinical excellence, scientific leadership, and physician-led innovation.

We envisage our mission in driving venture creation, design partnership and boosting external biomedical innovation via access to Hadassah’s unique facilities, data and bio assets.

Focus Areas

Cell Therapy
Cell Therapy
Ophthalmology
Ophthalmology
Cardiology
Cardiology
Deep Biology
Deep Biology
Oncology
Oncology
Immunotherapy
Immunotherapy
Multi-Omics
Multi-Omics

For VCs

Co-Development and Venture Creation with Leading Hadassah Innovation Hubs
Cell Therapy
Cardiology
innovation lab
Ophthalmology
Ophthalmology
innovation lab
Cardiology
Oncology &
Immunotherapy center
Deep Biology
Robotics
Innovation lab
Oncology
AI Center
(Launching)
Clinical Data Research Unit
Clinical Data Research Unit

Portfolio for investment

HighRad

HighRAD provides an Intelligent Computer Assessment Support (iCAS )solution for a short and accurate assessment in the radiological follow-up of common pathologies for multiple organs and modalities.​ HighRAD’s products are designed around its novel Region of Difference (ROD ) generic platform and methodology for automatic, robust, and accurate lesion changes analysis in longitudinal volumetric scans, including CT and MRI scans. The ROD     technology was born from the collaboration of Prof. Leo Joskowicz, Head of the Computer-Assisted Surgery and Medical Image Processing Laboratory at the Hebrew University and Prof. Jacob Sosna, MD, Head of CT, and Director of the 3D Imaging Laboratory at Hadassah Medical Center.

EMRIS Pharma

EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. The technology originates from collaboration between Dr. Sharon Merims, senior dermatologist and Head of the skin toxicity clinic at the Sharett Institute of Oncology at Hadassah Medical Center and Prof. Ofra Benny, an associate professor at the Institute for Drug Research in the School of Pharmacy at the Hebrew University.

EverlyBio

EverlyBio, spun off in partnership with  VLX Ventures, is leveraging deep molecular data and utilizing computational biology to drive advancements in in vitro fertilization (IVF). The company aims to develop standardized diagnostics, improve implantation success rates, and identify novel biological interventions during the IVF process. This remarkable progress stems from a tri-lateral collaboration by Dr. Tal Imbar, Head of the Fertility Preservation Service at Hadassah IVF Unit, Prof. Yael Heifetz, Hebrew University, and Prof. Noam Shomron, Tel Aviv University.

OrSight

OrSight  is developing a treatment for Age-related Macular Degeneration (AMD), one of the leading causes of blindness worldwide. The novel treatment offers a potentially higher effectiveness solution compared to existing treatments, and is aimed to significantly improve patient compliance, a main problem with the current standard of care. The company was co-founded by Prof. Itay Chowers, Chairman of the Hadassah Department of Ophthalmology, and Prof. Ofra Benny from the Hebrew University of Jerusalem. The company was established as part of NGT Healthcare Fund II in 2023.

GenoCure AI

GenoCure.AI Ltd, the latest spin-off from Hadasit, is set to transform AI-driven precision oncology.
Co-founded by Prof. Shai Rosenberg, Head of the Unit for AI in Oncology and Head of the Hadassah Laboratory of Computational Biology of Cancer, along with Eitan Rubinow and Dr. Eitan Eliram, the company harnesses cutting-edge ML models like MESiCA and STAMP to translate DNA and RNA tumor sequencing data into actionable clinical recommendations and pharmacological clinical trials optimization.
GenoCure.AI’s AI engine is aimed to empower oncology professionals with clinico-Genomic insights, including mutational signatures, immunotherapy response predictions, and drug resistance profiles. For pharmaceutical companies, it offers advanced tools to accelerate oncology therapeutic development.

HepaCure Pharma

Hepacure Pharma is developing a novel peptide therapy targeting fatty liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). The HepaCure Pharma is a spinout company developed from the groundbreaking research of Prof. Rifaat Safadi and his team member Dr. Johnny Amer at the Hadassah Medical Center Liver Institute.

NAFLD encompasses conditions marked by excess fat in the liver, increasing the risk of serious health issues like diabetes and kidney disease. Advanced NAFLD forms, such as non-alcoholic steatohepatitis (NASH), lead to inflammation, fibrosis, and, in some cases, incurable carcinoma.
Hepacure’s therapy centers on a peptide called Luji, which targets fibrosis and reactivates immune responses in the liver. This peptide blocks key proteins in the fibrosis pathway and reactivates natural killer (NK) cells, enabling them to target hepatic stellate cells (HSCs), which contribute to fibrosis. Research highlights Neuroligin-4 (NLGN4X) as a factor in NK cell inhibition, leading to fibrosis progression. Luji modulates the NLGN4-Nrx1β protein interaction, aiming to prevent fibrosis advancement.

CardioVia

CardioVia provides the physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​By using cutting edge technologies with the simplest ideas CardioVia will facilitate performance of surgeries on the outer surface of the heart like never seen before.

SwiftDuct

SwiftDuct  is a spinoff of the Biodesign program operated by Hadassah Medical Center and The Hebrew University of Jerusalem. Hadassah physicians Dr. Yeugeny Plotkin  and Dr. Abed Khalaileh are one of the inventors  of the primary technology.  SwiftDuct’s technology is designed to empower gastroenterologists to take the right path directly to the bile duct, safely, efficiently, and quickly while reducing the risks of side effects and radiation exposure to patients and medical teams. The SwiftDuct Navigation Kit, which includes the Swiftome™ and the SwiftGlide™ is designed to provide exceptional navigation capabilities for gastroenterologists to perform faster, easier and safer ERCP procedures. SwiftDuct is a portfolio company of MEDX Xelerator and located at MEDX’s North Branch in Sakhnin, Israel.

Dio Tree

Dio Tree is developing first-in-class small molecule for the treatment of ovarian cancer. The technology is based on inhibition of the enzyme DIO3, a major driver in many types of cancer, specifically, ovarian cancer. The molecule was developed by: Prof. Bernard Lerer, Founder of Hadassah’s Biological Psychiatry Laboratory and Hadassah BrainLabs;Dr. Tzuri Lifschytz of the Biological Psychiatry Laboratory; and Prof. Govindasamy Mugesh from the National Institute of Science in India. Prof. Lerer joined forces with Prof. Osnat Ashur-Fabian, Director of the Laboratory for Applied Oncology Research at the Hematology Institute at Meir Hospital, who led the preclinical study. This unique collaboration led to the establishment of DioTree.

NeuroGenesis

NeuroGenesis is a clinical stage cellular therapy company focusing on a proprietary subpopulation of bone marrow stem cells that are selected and enhanced to become remyelinating & regenerative biofactory cells. The platform NG CELL™️ technology is optimized to treat central nervous system diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

Exosomm

Inspired by the virtues of breast milk and its unique health properties, EXOSOMM is developing an exciting step towards care and quality of life for patients suffering from inflammatory bowel diseases (IBD). The company is backed by Prof. Shimon Reif, Head of the Department of Pediatrics at Hadassah, Dr. Regina Golan-Gerstl, Director of the Hadassah Pediatric Laboratory, and Dr.Yaffa Elbaum-Shiff, Deputy Director of the Department of Nutrition at Tel Aviv Medical Center, and led by CEO Netta Granot. Exosomm harnesses the natural properties of milk-derived nano-molecules found naturally in mammalian milk by creating a portfolio of exosomes-based nutritional solutions. The company was established in partnership with the Galil-Ofek incubator.

Noxon

Noxon is developing a groundbreaking drug to combat Idiopathic Pulmonary Fibrosis (IPF), a devastating disease characterized by lung fibrosis and limited survival. Through collaboration between Prof. Neville Berkman, Director of the Hadassah Department of Pulmonary Medicine and researchers from the Hebrew University of Jerusalem - Prof. Sara Goldstein and Prof. Amram Samuni,  a novel drug called 3-cabamoyl-proxyl (3-CP) has been discovered that holds immense potential to offer a safe and effective approach in the battle against IPF.

For Corporates and Startups

World-class biospecimen and multiomics resources

Organoid Center
Organoid
Center
Hadassah Cancer Research Institute
Hadassah Cancer Research Institute
Tissue/Liquid Biobanks & Molecular Pathology
Tissue/Liquid Biobanks & Molecular Pathology

Data Access and Clinical setting

Real World Evidence to boost your business

Real World Evidence to boost your business

  • 40 years of multi-ethnic EHR
  • 3.5 M Patients Data
  • Diverse Jerusalem population
  • Compliance with GDPR requirements


Develop, Validate and Integrate your solution within
                                        a hospital setting

Develop, Validate and Integrate your solution within a hospital setting

  • Accelerator powered by IBM for early stage startups
  • Aligned with Hadassah IT unit
  • Matched with real clinical needs
  • Supported by leading physicians and industry experts
  • Fast track to clinical adoption and impact

Among our partners

We invite biomedical companies,
  VCs and Corporates
to partner with us!

Contact
Hadasit

Jerusalem BioPark, Hadassah Ein Kerem POB 12000, Jerusalem 91120, Israel
Tel. +972-2-6778757 Fax. +972-2-6437712 Email. infohadasit@hadassah.org.il